Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2025)

BridgeBio Pharma's Current Deferred Revenue history spans 5 years, with the latest figure at $54.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 13475.0% year-over-year to $54.3 million; the TTM value through Dec 2025 reached $54.3 million, up 13475.0%, while the annual FY2025 figure was $54.3 million, 13475.0% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $54.3 million at BridgeBio Pharma, up from $9.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $100.0 million in Q2 2024 and bottomed at $400000.0 in Q4 2024.
  • The 4-year median for Current Deferred Revenue is $10.5 million (2025), against an average of $23.6 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 93.44% in 2024 before it surged 13475.0% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $19.8 million in 2022, then plummeted by 69.21% to $6.1 million in 2023, then tumbled by 93.44% to $400000.0 in 2024, then soared by 13475.0% to $54.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Current Deferred Revenue are $54.3 million (Q4 2025), $9.1 million (Q3 2025), and $10.5 million (Q2 2025).